Design Therapeutics, Inc.·4

Apr 1, 6:25 PM ET

Quan Venture Fund II, L.P. 4

4 · Design Therapeutics, Inc. · Filed Apr 1, 2021

Insider Transaction Report

Form 4
Period: 2021-03-30
Transactions
  • Conversion

    Common Stock

    [F1]
    2021-03-30+4,439,8394,439,839 total
  • Conversion

    Common Stock

    [F1]
    2021-03-30+280,9914,720,830 total
  • Conversion

    Series A Preferred Stock

    [F1]
    2021-03-307,236,9380 total
    Common Stock (4,439,839 underlying)
  • Conversion

    Series B Preferred Stock

    [F1]
    2021-03-30458,0160 total
    Common Stock (280,991 underlying)
Footnotes (1)
  • [F1]All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.
Signature
QUAN VENTURE FUND II, L.P., By: QUAN VENTURE PARTNERS II, L.L.C., its general partner, By: /s/ Stella Xu, Managing Director|2021-03-31

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION